海森药业 (001367)

Zhejiang Haisen Pharmaceutical Co., Ltd.

ASZ

Tags

Individual ShareholdingsChemical PharmaceuticalsMicro and Small Cap StocksMicro Cap Selected StocksPlanned Reduction of HoldingsHigh-Performing StocksShenzhen Recently Listed StocksSZSE Medicine Equal Weight IndexShenzhen A-Share Pharmaceutical IndexCSI All-share Pharmaceutical Sector IndexPharmaceutical & Health 100 IndexZhejiang

K-Line Chart

No K-line data available

Company NameZhejiang Hisun Pharmaceutical Co., Ltd.
Listing Date2023-04-10
Issue Price44.48RMB
Registered Capital15235.1210k RMB
Legal RepresentativeWang Shiyue
Registered AddressXiangtan Village, Liushi Street, Dongyang City, Zhejiang Province
IndustryChemical Pharmaceuticals
Main BusinessResearch, development, production, and sales of chemical drug active pharmaceutical ingredients (APIs) and intermediates.
Company ProfileZhejiang Hisun Pharmaceutical Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and sales of chemical drug active pharmaceutical ingredients (APIs) and intermediates. After years of development, the company has established a product portfolio primarily focused on APIs for the digestive system, antipyretic analgesics, and cardiovascular diseases, supplemented by APIs for antidepressants and antibacterials, with APIs and formulations for antivirals and non-steroidal anti-inflammatory drugs (NSAIDs) as preparatory products. The company's products cover a wide range, capable of meeting the diverse needs of domestic and international clients, laying a solid foundation for sustainable development. The company holds a total of 23 patents, including 18 invention patents. After years of management accumulation and market expansion, the company has become one of the major domestic manufacturers of products such as Sucralfate and Atorvastatin Calcium, and has achieved a significant market share in the global market. The company has obtained certifications from multiple countries and regions, including China's GMP certification, Japan's PMDA certification, and South Korea's MFDS certification. It has passed on-site inspections by the U.S. FDA and Mexico's COFEPRIS. Its main products have obtained the EU CEP certificate and India's CDSCO registration certificate. The company possesses mature technology and extensive experience in quality control, enjoying a certain level of recognition and reputation in the market.

Stock Details

1. Key Indicators

  • Total Shares(W): 15235.12
  • Circulating A-Shares(W): 3969.77
  • Earnings Per Share(RMB): 0.5900
  • Net Assets Per Share(RMB): 9.4267
  • Operating Revenue(W RMB): 35886.72
  • Total Profit(W RMB): 10236.66
  • Net Profit Attributable to Parent(W RMB): 8820.96
  • Net Profit Growth Rate(%): 1.45
  • Weighted Return on Equity(%): 6.3500
  • Operating Cash Flow Per Share(RMB): 0.7060
  • Undistributed Profit Per Share(RMB): 3.4357
  • Capital Reserve Per Share(RMB): 4.8124

2. Main Business

The main business covers:

  • Research, development, production, and sales of chemical pharmaceutical APIs and intermediates.

3. Company Basic Information

  • Company Name: Zhejiang Haisen Pharmaceutical Co., Ltd.
  • Listing Date: 2023-04-10
  • Industry: Pharmaceutical Manufacturing
  • Address: Xiangtan Village, Liushi Street, Dongyang City, Zhejiang Province
  • Website: www.haisenpharma.com
  • Company Profile: The company was restructured into a joint-stock company on October 11, 2017, and is primarily engaged in the research, development, production, and sales of chemical pharmaceutical APIs and intermediates.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 UBS AG QFII 50.42 1.30
2 BARCLAYS BANK PLC QFII 44.23 1.14
3 J.P.Morgan Securities PLC-自有资金 QFII 43.85 1.13
4 Goldman Sachs Group, Inc. QFII 27.86 0.72
5 MORGAN STANLEY & CO. INTERNATIONAL PLC. QFII 25.67 0.66
6 Huatai-PineBridge CSI 2000 Index Enhanced Securities Investment Fund A Fund 7.38 0.19
7 Shenwan Hongyuan Quantitative Small Cap Stock Securities Investment Fund (LOF) A Fund 3.04 0.08
8 Zhong Ou Small Cap Growth Mixed Securities Investment Fund A Fund 2.35 0.06
9 Huatai-PineBridge CSI 1000 Index Enhanced Securities Investment Fund A Fund 1.46 0.04
10 Minsheng Jiayin CSI All Share Index Enhanced Securities Investment Fund A Fund 0.71 0.02

5. Concept Sectors

  • Synthetic Biology
  • Margin Trading & Securities Lending
  • High-Performance Stock
  • Individual Shareholding
  • Proposed Reduction
  • Micro Portfolio Selection
  • Micro Small-Cap Stock

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information